Microacidophilus oligotrophic monocytogenes capable of improving ulcerative colitis and its application

By using Stenotrophomonas acidaminephila and its related products, the problem of treatment of ulcerative colitis was solved, and the effect of significantly alleviating colitis and liver pathological damage was achieved, and a new targeted treatment plan was provided.

CN117089501BActive Publication Date: 2024-11-29ZHEJIANG CHINESE MEDICAL UNIVERSITY

Patent Information

Application Number
CN202311267866.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-28
Publication Date
2024-11-29
Estimated Expiration
2043-09-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat ulcerative colitis, traditional drugs are not effective and have side effects, and there is a lack of targeted treatment plans.

Method used

Provided is a micro-eosinophila Stenotrophomonas acidaminephila CGMCC No. 26919 and its related products for the preparation of drugs to improve or treat ulcerative colitis, with the ability to antioxidant, anti-inflammatory and improve the intestinal mucosal barrier.

Benefits of technology

It significantly alleviates colon shortening and liver pathological damage caused by DSS-induced colitis, has strong antioxidant and anti-inflammatory capabilities, improves intestinal mucosal barrier function, and provides new probiotic treatment ideas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117089501B_ABST
    Figure CN117089501B_ABST
Patent Text Reader

Abstract

The present invention discloses Stenotrophomonas acidaminiphila and its application for improving ulcerative colitis, belonging to the field of microbial technology. The deposit number of the Stenotrophomonas acidaminiphila is CGMCC No.26919. It is found through experimental verification that the Stenotrophomonas acidaminiphila can significantly alleviate the shortening of the colon caused by DSS-induced colitis; improve the process of liver pathological damage caused by DSS-induced colitis; and also has strong antioxidant, anti-inflammatory and intestinal mucosal barrier improvement capabilities. It can be seen that the Stenotrophomonas acidaminiphila separated by the present invention has the potential to treat ulcerative colitis, providing a new probiotic drug for the treatment of ulcerative colitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, in particular to oligotrophic microacidiotrophs capable of improving ulcerative colitis and application thereof. Background Art

[0002] Ulcerative colitis (UC) is a chronic non-specific inflammatory disease of the colon and rectum. Its pathogenesis is relatively complex. It is speculated that it is mainly related to factors such as the environment, autoimmunity, psychological state, and intestinal flora. Among them, intestinal flora, as the main participant and regulator of intestinal homeostasis, is usually most closely related to the occurrence of UC. The main symptoms of UC include abdominal pain, diarrhea, blood in the stool, constipation, weight loss, etc., and complications often occur after the onset of the disease, and the negative impact it brings cannot be underestimated. Due to the complexity and recurrence of UC itself, it is difficult to cure and is clinically called "immortal cancer". In recent years, with the rapid development of society, the increase in living pressure, environmental changes, and the emergence of new diseases have caused the incidence of UC to rise day by day, and the number of people with the disease has gradually expanded. Therefore, it is urgent and necessary to comprehensively study the pathogenesis of UC and take effective prevention and treatment measures.

[0003] Ulcerative colitis (UC) and Crohn's disease (CD) together constitute chronic inflammatory bowel disease (IBD). The main differences between the two are the following two points: in terms of the affected parts, UC often affects only the colon and rectum, while CD affects a wide range of parts, and every part of the upper and lower digestive tract may be invaded by this disease; in terms of the layers of the colon affected, UC only affects the innermost wall of the colon, while CD can invade the entire colon. At present, there are general treatments for UC and CD, but the effect is not good, and targeted drugs are still needed for treatment. The targeted drugs for the two are not the same. For example, for CD, the main ones are biological agents such as ustekinumab (UST), vedolizumab (VDZ), infliximab (IFX) or drugs such as thalidomide, tacrolimus, and methotrexate. For UC, Chinese herbal prescriptions such as Huangcen Decoction and Shaoyao Decoction or drugs such as mesalazine, sulfasalazine, and 5-aminosalicylic acid can be used for treatment. New studies have shown that the use of the above prescriptions or drugs combined with probiotics such as Bifidobacterium and Lactobacillus plantarum to treat UC has the effects of reducing drug side effects, improving drug efficacy, regulating intestinal flora, and maintaining intestinal homeostasis, which is a new research direction for improving and treating UC. On this basis, we can further explore the effects of bacteria with or potentially beneficial activities on UC. The scheme of intervening in the occurrence and development of UC by acting on the intestine through certain metabolic activities of the bacteria themselves can bring new ideas for the targeted treatment of UC.

[0004] Stenotrophomonas acidaminiphila has multiple functions, and its known use is to degrade various compounds. For example, the invention of CN106967641A, "A Stenotrophomonas acidaminiphila and its application", discloses that Stenotrophomonas acidaminiphila SP-3 is used for the degradation of azo dye wastewater; the invention of CN109762761A, "Stenotrophomonas acidaminiphila for efficient degradation of aflatoxin B1 and its application", discloses that Stenotrophomonas acidaminiphila A-2 can degrade aflatoxin B1. However, there is no report on the use of Stenotrophomonas acidaminiphila for ulcerative colitis. Summary of the invention

[0005] The purpose of the present invention is to provide a microacidophilic oligotrophic mononas having the effect of improving ulcerative colitis and its application, so as to solve the problems existing in the above-mentioned prior art. The microacidophilic oligotrophic mononas can significantly alleviate the shortening of the colon caused by DSS-induced colitis; as well as the process of liver pathological damage, and also has strong antioxidant, anti-inflammatory and intestinal mucosal barrier improvement capabilities, and can effectively alleviate or treat ulcerative colitis.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides a microacidophilic oligotrophic mononas (Stenotrophomonas acidaminiphila), the preservation number of the bacterium is CGMCC No.26919, the preservation time is March 28, 2023, the preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0008] The present invention also provides the use of the microacidophilic oligotrophic monosporus or its related products in the preparation of drugs for improving or treating ulcerative colitis. The related products include fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0009] The present invention also provides the use of the microacidophilic oligotrophic monosporus or its related products in the preparation of antioxidant drugs. The related products include fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0010] The present invention also provides the use of the microacidophilic oligotrophic monosporus or its related products in the preparation of anti-inflammatory drugs. The related products include fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0011] The present invention also provides the use of the microacidophilic oligotrophic monosporus or its related products in the preparation of a drug for restoring intestinal barrier function. The related products include fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monosporus.

[0012] The present invention also provides a drug for improving or treating ulcerative colitis, which contains the microacidophilic oligotrophic monospora or its related products, wherein the related products include fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monospora.

[0013] The present invention also provides an antioxidant drug, which contains the microacidophilic oligotrophic monospora or its related products, wherein the related products include fermentation liquid, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monospora.

[0014] The present invention also provides an anti-inflammatory drug, which contains the microacidophilic oligotrophic monospora or its related products, wherein the related products include fermentation liquid, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monospora.

[0015] The present invention also provides a drug for restoring intestinal barrier function, which contains the microacidophilic oligotrophic monospora or its related products, wherein the related products include fermentation broth, inactivated bacteria, bacterial suspension or secondary metabolites of the microacidophilic oligotrophic monospora.

[0016] The present invention discloses the following technical effects:

[0017] The present invention isolates and screens a new strain of oligoacidophilic monospora ZCMU-Sa01 from the feces of a six-year-old child. Experimental verification shows that the strain can significantly alleviate the shortening of the colon caused by DSS-induced colitis; improve the progression of liver pathological damage caused by DSS-induced colitis; and also has strong antioxidant, anti-inflammatory, and intestinal mucosal barrier improvement capabilities. It can be seen that the oligoacidophilic monospora ZCMU-Sa01 isolated in the present application has the potential to treat ulcerative colitis, providing a new probiotic drug for the treatment of ulcerative colitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0019] Figure 1 This is the colony morphology of Oligotrophomonas microacidophilus ZCMU-Sa01;

[0020] Figure 2 This is the Gram-stained bacterial morphology of Oligotrophomonas microacidophilus ZCMU-Sa01;

[0021] Figure 3 This is the electrophoresis identification diagram of 16S rDNA of Oligotrophomonas microacidophilus ZCMU-Sa01;

[0022] Figure 4 This is an organizational diagram of the effect of ZCMU-Sa01 on the colon length of mice;

[0023] Figure 5 This is a statistical diagram of the effect of Oligotrophomonas acidophilus ZCMU-Sa01 on the colon length of mice;

[0024] Figure 6The effect of Oligotrophomonas acidophilus ZCMU-Sa01 on malondialdehyde (MDA) and superoxide dismutase (SOD) in the colon of mice;

[0025] Figure 7 The effect of ZCMU-Sa01 on inflammatory factors (TNF-α, IL-1β, IL-6) in the colon of mice;

[0026] Figure 8 The effect of Oligotrophomonas acidophilus ZCMU-Sa01 on tight junction protein genes (ZO-1 and Occludin-1) in mouse colon;

[0027] Fig. 9 The effect of Oligotrophomonas acidophilus ZCMU-Sa01 on the expression of mucin gene (MUC2) in mouse colon. DETAILED DESCRIPTION

[0028] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0029] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0030] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0031] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0032] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0033] Example 1 Screening and identification of oligotrophic microacidophilic bacteria ZCMU-Sa01:

[0034] 1. Sample source

[0035] The strain used in the present invention was isolated from the feces of a six-year-old child.

[0036] 2. Isolation and purification of strains

[0037] Take out the stored strain from the -80℃ refrigerator and inoculate it onto fresh LB medium at pH 6 by streaking. Invert and incubate in a 37℃ constant temperature incubator for 2-3 days. When a single clone grows out, pick it with an inoculation loop and inoculate it onto fresh LB medium at pH 6 by streaking. After a single clone grows out, store it in a 4℃ refrigerator for later use.

[0038] 3. Identification of Oligotrophomonas microacidophilus ZCMU-Sa01

[0039] 3.1 Colony characteristics

[0040] After the isolated and purified strain was cultured in LB solid medium for 48 hours, the colonies were nearly round, white, uniform in size, with smooth and neat edges without wrinkles, and a moist surface. Figure 1 .

[0041] 3.2 Morphology under microscope

[0042] The colony of the isolated and purified strain was smeared: Gram staining was negative, non-spore-forming, round-ended short rods, single or short chain, see Figure 2 .

[0043] 3.3 16S rDNA identification

[0044] The target strain genomic DNA was extracted using the Ezup column bacterial genomic DNA extraction kit. The extracted lactic acid bacteria genomic DNA was used as a template for PCR amplification. The bacterial universal primers 27F and 1492R were used to perform PCR experiments on 16S rDNA. After the PCR reaction was completed, the PCR product was taken for agarose gel detection and photography. The length of the amplified fragment was about 1.2 kbp, as shown in Figure 2. Figure 3The PCR product was sent to Zhejiang Tianke High-tech Development Co., Ltd. for sequencing, and the result is shown in SEQ ID NO.1. The BLAST sequence comparison was performed on the NCBI website, and the results showed that the sequence had a homology of more than 99% with the 16S rDNA sequence identified by Microacidophilic Oligotrophomonas. The sequence comparison results of the strain were combined with the physiological and biochemical results to determine that the screened strain was Microacidophilic Oligotrophomonas, and was named Microacidophilic Oligotrophomonas ZCMU-Sa01.

[0045] SEQ ID NO.1 is: AGTCGAGC GCAGGAAG CCGTCTGA ACCCTTCG GGGGGACGACGGTGGAATGAGCGG CGGACGGG TGAGTAAC ACGTAAAG AACCTGCC CATAGGTCTGGGATAACCACGAGA AATCGGGG CTAATACC GGATGTGT CATCGGAC CGCATGGT CCGCTGATGAAAGGCG CTCCGGCG TCGCCCAT GGATGGCT TTGCGGTG CATTAGCT AGTTGGTG GGGTAACGGCCCACCAAGGCGACG ATGCATAG CCGACCTG AGAGGGTG ATCGGCCA CACTGGGA CTGAGACACGGCCCAG ACTCCTAC GGGAGGCA GCAGTAGG GAATCTTC CACAATGG ACGAAAGTCTGATGGAGCAACGCC GCGTGAAC GATGAAGG CTTTCGGG TCGTAAAG TTCTGGTGTAAGGGAAGAACAAGT GCCGCAGG CAATGGCG GCACCTTG ACGGTACC TTGCGAGA AAGCCACGGCTAACTA CGTGCCAG CAGCCGCG GTAATACG TAGGTGGC AAGCGTTG TCCGGAATTATTGGGCGTAAAGCG CGCGCAGG CGGACTCT TAAGTCTG ATGTGAAAGCCCCCGG CTCAACCGGGGAGGGC CATTGGAA ACTGGGAG GCTTGAGT ATAGGAGAGAAGAGTG GAATTCCACGTGTAGCGGTGAAAT GCGTAGAG ATGTGGAG GAACACCAGTGGCGAAGGCGACTC TTTGGCCT ATAACTGACGCTGAGG CGCGAAAG CGTGGGGAGCAAACAG GATTAGAT ACCCTGGT AGTCCACG CCGTAAACGATGAGTG CTAGGTGT TGGAGGGT TTCCGCCC TTCAGTGC TGAAGCTA ACGCATTAAGCACTCCGCCTGGGG AGTACGGT CGCAAGGC TGAAACTC AAAGGAAT TGACGGGG ACCCGCACAAGCGGTGGAGCATGT GGTTTAAT TCGAAGCAACGCGAAG AACCTTAC CAACTCTT GACATCCCC CTGACCGGTACAGAGA TGTACCTT CCCCTTCG GGGGCAGG GGTGACAG GTGGTGCATGGTTGTC GTCAGCTCGTGTCGTG AGATGTTG GGTTAAGT CCCGCAAC GAGCGCCAACCCTTGT CCTTAGGTT GCCAGCATTTGGTTGG GCACTCTAGGGAGACT GCCGGTGACAAACCGG AGGAAGGT GGGGATGACGTCAAAT CATCATGCCCCTTATG AGTTGGGC TACACACG TGCTACAA TGGACGGT ACAAAGGG CAGCGAAG CCGCGAGGTGGAGCCAATCCCAGAAAGCCGTT CTCAGTTC GGATTGCA GGCTGCAACTCGCCTG CATGAAGT CGGAATCGCTAGTAAT CGCAGGTC AGCATACT GCGGTGAA TACGTTCC CGGGTCTT GTACACAC CGCCCGTCACACCACG AGAGTTTG CAACACCC GAAGTCGG TGAGGTAA

[0046] The above-mentioned isolated oligotrophic microacidophilic bacteria ZCMU-Sa01 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on March 28, 2023, with the deposit number CGMCC No.26919, and the deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0047] Example 2 Preparation of the bacterial solution of oligotrophomonas microacidophilus ZCMU-Sa01

[0048] The preparation method of ZCMU-Sa01 bacterial solution is as follows: the strain ZCMU-Sa01 stored in the glycerol tube is first activated by streaking on the LB agar plate for 2 to 3 times, and then a single colony is picked and expanded in LB liquid culture medium at 37°C for 18 to 24 hours until the concentration of the bacterial solution reaches 10 9 ~10 10 CFU / mL, as a bacterial suspension (live bacterial solution). In actual use, physiological saline can be used to adjust the bacterial solution to the required concentration, for example, to 5×10 9 CFU / mL.

[0049] Preparation method of inactivated ZCMU-Sa01 bacterial solution: inactivate the above-mentioned ZCMU-Sa01 bacterial suspension at 121° C. under high temperature and high pressure for 30 min to obtain the inactivated ZCMU-Sa01 bacterial solution.

[0050] Example 3: Microacidophilus oligotrophomonas ZCMU-Sa01 improves DSS-induced ulcerative colitis

[0051] 1. Experimental Materials

[0052] Experimental animals: Twelve C57BL / 6 male mice were purchased from Shanghai Slake Experimental Animal Center, company license number: SCXK (Shanghai) 2013-0016, and were kept in the Experimental Animal Center of Zhejiang Chinese Medical University in an SPF environment.

[0053] Reagents: ALT kit (catalog number: C009-2 Nanjing Jiancheng Bioengineering Institute), AST kit (catalog number: C010-2 Nanjing Jiancheng Bioengineering Institute), free fatty acid kit (catalog number: A042-2-1 Nanjing Jiancheng Bioengineering Institute), tissue triglyceride kit (catalog number: E1013 Beijing Prilai Gene Technology Co., Ltd.), malondialdehyde assay kit (catalog number: A003-1 Nanjing Jiancheng Bioengineering Institute), total superoxide dismutase assay kit (catalog number: A001-1 Nanjing Jiancheng Bioengineering Institute), catalase detection kit (catalog number: A001-1, Nanjing Jiancheng Bioengineering Institute), IL-1β Elisa kit (catalog number: PI301, Shanghai Biyuntian Co., Ltd.), TNF-α Elisa kit (catalog number: PI301, Shanghai Biyuntian Co., Ltd.).

[0054] 2. Experimental methods

[0055] After C57BL / 6 mice were adapted to feeding in an SPF animal laboratory for one week, the 8-week-old C57BL / 6 mice were randomly divided into 3 groups, with 4 mice in each group, namely control group (Control), DSS-induced group (DSS), DSS-induced + Stenotrophomonas acidophilus ZCMU-Sa01 group (DSS+Sa01), and DSS-induced + inactivated Stenotrophomonas acidophilus ZCMU-Sa01 group (DSS+Sa01 (heat-killed)).

[0056] The control group was fed with distilled water for 1 week, and the DSS-induced group, DSS-induced + Microacidophilic Oligotrophomonas ZCMU-Sa01 group, and DSS-induced + inactivated Microacidophilic Oligotrophomonas ZCMU-Sa01 group were fed with DSS for 1 week. During this period, the DSS-induced + Microacidophilic Oligotrophomonas ZCMU-Sa01 group was gavaged with 0.2 mL of Microacidophilic Oligotrophomonas ZCMU-Sa01 (0.2 mL of bacterial solution contained 109 CFU of ZCMU-Sa01, the solvent was normal saline); the DSS-induced + inactivated Stenotrophomonas acidophilus ZCMU-Sa01 group was gavaged with 0.2 mL of inactivated Stenotrophomonas acidophilus ZCMU-Sa01 (the solvent was normal saline) once a day.

[0057] The feed consumed by the mice was replaced with new feed every two days, and the physiological phenomena of the mice were observed every day. After feeding, the mice were anesthetized with 1% pentobarbital intraperitoneal injection, blood was drawn from the inferior vena cava to measure biochemical indicators such as ALT and AST, and liver and intestinal tissues of the mice were taken for measurement of related indicators.

[0058] 3. Index determination

[0059] 3.1 Colon H&E staining

[0060] Fresh colon tissue of animals was fixed with 4% paraformaldehyde, dehydrated with gradient alcohol and permeabilized with xylene before paraffin embedding. The embedded paraffin was sliced, and 4 μm slices were taken for H&E staining, dewaxed with xylene, and gradually dehydrated with ethanol: xylene (I) 5min; xylene (II) 5min; 100% ethanol 2min; 95% ethanol 1min; 80% ethanol 1min; 75% ethanol 1min; washed with distilled water for 2min. Hematoxylin staining for 5min, rinsed with water, differentiated with hydrochloric acid ethanol for 30s, soaked in water for 15min, and placed in eosin solution for 2-3min. Conventional dehydration, transparency, and sealing: 95% ethanol (I) 30s; 95% ethanol (II) 30s; 100% ethanol (I) 30s; 100% ethanol (II) 1min; xylene 15min; neutral resin sealing.

[0061] 3.2 Malondialdehyde (MDA) detection

[0062] Refer to the instructions of the malondialdehyde assay kit and operate as follows:

[0063] Accurately weigh the colon tissue, add 9 times the volume of physiological saline according to the ratio of weight (g): volume (mL) = 1:9, cut the tissue into pieces, prepare homogenate in an ice water bath, centrifuge at 3000 rpm for 10 min, and take the supernatant, i.e. 10% homogenate supernatant for testing. Add 0.1 mL of anhydrous ethanol to the blank tube, add 0.1 mL of 10 nmol / mL standard to the standard tube, add 0.1 mL of test sample to the assay tube and control tube, add 0.1 mL of reagent 1 to these four tubes respectively, mix well, add 3 mL of reagent 2 application solution to these four tubes, add 1 mL of reagent 3 application solution to the blank tube, standard tube, and assay tube, and add 1 mL of 50% glacial acetic acid to the control tube. Mix well, incubate at 95℃ for 40 min, take out and cool, then centrifuge at 3500-4000 r / min for 10 min to take the supernatant, and measure the OD value at 532 nm. Calculate the MDA content between each group according to the calculation formula.

[0064] 3.3 Detection of superoxide dismutase (SOD)

[0065] Refer to the instructions of the total superoxide dismutase assay kit and proceed as follows:

[0066] Take 10% colon homogenate supernatant for testing. Add 1mL of reagent 1 application solution to two tubes, add 0.05mL of sample to the test tube, add 0.05mL of distilled water to the control tube, add 0.1mL of reagent 2, reagent 3, and reagent 4 application solution to the two tubes respectively, mix thoroughly with a vortex mixer, incubate at 37℃ for 40min, and add 2mL of color developer to the two tubes respectively. Mix well, leave at room temperature for 10min, and measure the OD value at a wavelength of 550nm.

[0067] 3.4 Elisa detection of plasma TNF-α, IL-1β, and IL-6

[0068] Total protein of colon segments was extracted by homogenization in 5 volumes (w / v) of ice-cold saline followed by centrifugation at 12,000 × g for 15 min. Levels of tumor necrosis factor-α (TNF-α), interleukin IL-1β, and IL-6 were measured using corresponding ELISA kits. All ELISA kits were purchased from Wuhan Service Bioengineering Co., Ltd. (Wuhan, China).

[0069] 3.5 Real-time PCR

[0070] (1) Take out the tissue from the -80°C freezer and place it in an ice box. Use an electronic balance to weigh about 0.02 g of tissue into an EP tube and precool the centrifuge at 4°C.

[0071] (2) Add 1 mL of Trizol and 3 steel beads to the EP tube containing the tissue block, grind with a grinder, remove the liquid, pour out the steel beads, and react at room temperature for 10 min;

[0072] (3) Add 200 μL of chloroform to the EP tube, shake vigorously for 30 seconds, and place on ice for 5-10 minutes;

[0073] (4) After standing, place the centrifuge tube in a 4°C centrifuge at 12,000 rpm for 15 min;

[0074] (5) Pipette the aqueous phase (supernatant) of the centrifuged sample into a new 1.5 mL centrifuge tube;

[0075] (6) Add an equal volume of isopropanol solution to the centrifuged solution, gently invert to mix, and let stand at -20°C for 20 min;

[0076] (7) Take out the sample from -20°C and centrifuge it at 12000 rpm and 4°C for 15 min;

[0077] (8) After centrifugation, discard the supernatant to obtain a white (or colorless and transparent) precipitate. Add 100-300 μL of pre-cooled 75% ethanol prepared with DEPC water along the inner wall of the centrifuge tube and wash 2-3 times.

[0078] (9) After discarding the liquid, air-dry at room temperature for about 15 min, add 20-50 μL of pre-cooled DEPC water to the centrifuge tube to dissolve the air-dried precipitate (RNA) at the bottom, and store in a -20°C refrigerator for later use;

[0079] (10) Use an ultra-micro UV spectrophotometer to measure the RNA concentration, record the results and calculate the sample loading amount for each group;

[0080] (11) As shown in Table 1, the corresponding reaction solution in the reverse transcription kit was added for premixing, and the sample was added for reverse transcription. After shaking and centrifugation, the sample was placed in a PCR instrument. The corresponding PCR reaction conditions were set according to the reverse transcription kit. The cDNA sample after reverse transcription by the reverse transcription instrument was placed in a -20°C refrigerator for future use;

[0081] (13) Use a 0.2 mL fluorescent quantitative PCR eight-tube concatenation, add the reactants, use cDNA as a template, and use a fluorescent quantitative PCR amplification instrument to amplify the experimental target gene and perform fluorescent quantitative PCR determination;

[0082] (14) The mixed reactants were shaken and mixed, and after centrifugation, the eight-tube strip was placed in a qRT-PCR reactor. The PCR reaction program was set as follows: pre-denaturation: 94°C, 5 min; denaturation: 94°C, 30 s, 60°C, 30 s, 72°C, 30 s, 40 cycles; extension: 72°C, 5 min, stored at 4°C;

[0083] (15) According to 2 -ΔΔCT The expression changes of target genes were calculated.

[0084] 4. Experimental results:

[0085] like Figure 4 and Figure 5 As shown, the colon lengths of the AF+Sa01 group and the AF+Sa01(Heat-killed) group were similar, but the colon lengths of the two groups were greater than that of the AF group. The results showed that ZCMU-Sa01 could significantly alleviate the shortening of the colon caused by DSS-induced colitis.

[0086] like Figure 6 As shown in the figure, the microacidophilic oligotrophic mononas ZCMU-Sa01 has a strong antioxidant capacity. Under normal circumstances, the antioxidant enzymes in the natural antioxidant defense system of the organism can work synergistically with the antioxidants in the diet or medicine to remove peroxides. The most important antioxidant enzymes include superoxide dismutase (SOD). SOD is responsible for dismutating superoxide anions into hydrogen peroxide, thereby preventing the production of highly toxic hydroxyl radicals. On the other hand, the level of lipid peroxidation product MDA is detected to indirectly determine the severity of free radical attack on cells.

[0087] like Figure 7 As shown, the results showed that ZCMU-Sa01 has anti-inflammatory effects. By detecting the levels of TNF-α, IL-1β and IL-6 in the blood, it was shown that DSS-induced colitis would increase the expression of inflammatory factors in the intestinal environment, while ZCMU-Sa01 could significantly inhibit inflammation, indicating that ZCMU-Sa01 has anti-inflammatory ability.

[0088] like Figure 8 and 9As shown in the results, the microacidophilic oligotrophic mononas ZCMU-Sa01 has the ability to improve the intestinal mucosal barrier. Tight junctions are the main connection between intestinal epithelial cells and play an important role in maintaining the mechanical barrier and permeability of the intestinal mucosal epithelium. Tight junction proteins are important protein molecules that constitute the intestinal mucosal barrier and determine the permeability of the intestinal wall, and have a great influence on the composition and function of tight junctions. Among them, ZO-1 and Occludin-1 are important factors that constitute tight junctions between cells. Intervention with microacidophilic oligotrophic mononas ZCMU-Sa01 significantly restored the reduced gene expression of ZO-1 and Occludin-1 caused by DSS-induced colitis. Under normal circumstances, goblet cells continuously produce a large amount of MUC2 protein to form a mucus protective layer; when DSS-induced colitis occurs, the goblet cell membrane is reduced or even exhausted, resulting in a decrease in the gene expression of MUC2 and a thinning of the mucus layer, thereby greatly weakening the protective function of the intestinal barrier. Intervention with Oligotrophomonas acidophilus ZCMU-Sa01 can upregulate the expression of MUC2 gene in DSS-induced model mice, promote their mucosal repair, increase the intestinal anti-inflammatory ability, and act on the intestinal mucosal barrier.

[0089] Example 4 Confirmation of acid resistance and bile resistance of oligotrophomonas microacidophilus ZCMU-Sa01

[0090] 1. Acid resistance test

[0091] A single colony of ZCMU-Sa01 was selected and expanded in LB liquid medium at 37°C for 18 hours. The expanded bacterial suspension was inoculated into LB liquid medium at 1% and cultured at 37°C for 18 hours. The culture solution was centrifuged at 8000r / min for 5 minutes at 4°C to collect the bacteria, and then washed twice with PBS buffer (pH 6.8, 0.1mol / L). The bacteria were suspended in LB liquid medium adjusted to pH 3.0 in advance, and the initial viable count was corrected to about 10 8 CFU / mL (wavelength 600nm, OD=0.5), culture at 37℃ for 24h. Measure the absorbance of the strain at a wavelength of 600nm at 3h, 6h, 12h, and 24h. Measure the survival rate based on the number of live bacteria corresponding to the absorbance at a wavelength of 600nm within 24h.

[0092] The survival rate calculation formula is as follows:

[0093]

[0094] In the above formula, N0 is the viable count of the test strain at 0h (CFU / mL); N t It is the number of viable bacteria (CFU / mL) of the test strain within 24 hours.

[0095] 2. Bile salt tolerance test

[0096] The activated and enlarged suspension of ZCMU-Sa01 was inoculated into MRS liquid culture medium at a volume of 1%, cultured at 37°C for 18 h, vortexed and mixed, and the initial viable count was corrected to about 10 9 CFU / mL (wavelength 600nm, OD = 0.5). Inoculate 10% of the strain into MRS liquid medium containing 0.3% (m / v) ox bile salt (control is MRS liquid medium without ox bile salt), culture at 37°C for 24h, and measure the absorbance of the strain at a wavelength of 600nm at 3h, 6h, 12h, and 24h. The bile salt tolerance of the strain is expressed as the logarithm of the difference between the number of viable bacteria per milliliter of the medium containing bile salts and the number of viable bacteria per milliliter of the medium without bile salts at 24h (log CFU / mL), and the number of viable bacteria corresponds to its absorbance value at a wavelength of 600nm.

[0097] As shown in Table 1, the survival rate of ZCMU-Sa01 in LB medium with a pH of 3.0 was as high as 96.05%. The number of viable bacteria still reached 10 in an environment containing 0.3% ox bile salt. 8 CFU / mL or more indicates that it has good bile salt tolerance. Experiments have shown that ZCMU-Sa01 has a high gastrointestinal survival ability.

[0098] Table 1 Results of strain tolerance to acid and bile salts

[0099] strain Acid resistance (%) Bile salt tolerance (ΔLog CFU / mL) Microacidophilus oligotrophomonas Sa01 96.05 0.99

[0100] Probiotics must be able to survive a series of adverse environments such as gastric acid and bile in the gastrointestinal tract to play their probiotic effects. The microacidophilic oligotrophic mononas ZCMU-Sa01 provided by the present invention can grow and proliferate under the condition of pH 3.0, and can smoothly pass through the acidic environment in the stomach to reach the small intestine. At the same time, the microacidophilic oligotrophic mononas ZCMU-Sa01 can tolerate bile salts, and it can survive in the intestine, thereby effectively improving the intestinal flora and playing a hypoglycemic effect.

[0101] Example 5 Confirmation of Antibiotic Susceptibility of Oligotrophomonas microacidophilus ZCMU-Sa01

[0102] The concentration of the cultured cells after 18 hours is about 10 7 Add 1% of CFU / mL of the microacidophilic oligotrophic monocytogenes ZCMU-Sa01 bacterial suspension to the sterilized LB agar medium cooled to about 45°C, mix thoroughly, and add 15mL / dish quantitatively. After solidification, use tweezers to take the drug-sensitive paper and place it on the culture medium. Place the culture dish face up in a 37°C incubator and culture for 24 hours. Use the paper without antibiotics as a blank control. Measure the diameter of the inhibition zone. Repeat each three times.

[0103] The diameter of the inhibition zone of the sensitivity of ZCMU-Sa01 to antibiotics is shown in Table 2. According to the CLSI (2017) drug sensitivity test standard, ZCMU-Sa01 is sensitive to gentamicin, erythromycin, ciprofloxacin and chloramphenicol. It is intermediate for ampicillin and clindamycin. The experimental results show that ZCMU-Sa01 is sensitive to common antibiotics.

[0104] Table 2 Results of antibiotic sensitivity of Oligotrophomonas microacidophilus ZCMU-Sa01

[0105]

[0106] Note: S, sensitive; I, intermediate; R, resistant.

[0107] With the widespread use of antibiotics in clinical treatment, the drug resistance of oligotrophic microacidophilus is becoming more and more serious. Long-term intake of resistant oligotrophic microacidophilus will bring great difficulties to clinical treatment. The oligotrophic microacidophilus ZCMU-Sa01 provided by the present invention is sensitive to common antibiotics and will not cause harm to human health.

[0108] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Microacidophilus oligotrophomonas Stenotrophomonas acidaminiphila ) or its related products in the preparation of a drug for improving or treating ulcerative colitis, characterized in that: The related product is the fermentation liquid, inactivated bacterial cells or bacterial suspension of the microacidophilic oligotrophic monosporus; the preservation number of the microacidophilic oligotrophic monosporus is CGMCC No.26919.

2. A drug for improving or treating ulcerative colitis, characterized in that: It contains oligotrophic microacidophilic monospora or related products thereof, wherein the related products are fermentation liquid, inactivated bacterial bodies or bacterial suspension of oligotrophic microacidophilic monospora; the preservation number of the oligotrophic microacidophilic monospora is CGMCC No.26919.

Citation Information

Patent Citations

  • Stenotrophomonas acidaminiphila and application thereof

    CN106967641A

  • Stenotrophomonas acidaminiphila capable of efficiently degrading aflatoxin B1 and application thereof

    CN109762761A

  • Stenotrophomonas acidophilus capable of improving atherosclerosis and application thereof

    CN117050916A

  • Stenotrophomonas microacidophilus capable of improving APAP-induced drug-induced liver injury and application of stenotrophomonas microacidophilus

    CN117050917A

  • Stenotrophomonas microacidophilus capable of improving metabolic liver diseases and application of stenotrophomonas microacidophilus

    CN117070422A

Cited By

  • Stenotrophomonas acidophilus capable of improving atherosclerosis and application thereof

    CN117050916A

  • Microaerophilic oligotrophic pseudomonas with improved atherosclerosis and use thereof

    CN117050916B